FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc. is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FGEN
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.91 billion
  • Outstanding Shares: 69,944,000
Average Prices:
  • 50 Day Moving Avg: $27.00
  • 200 Day Moving Avg: $24.24
  • 52 Week Range: $14.50 - $29.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -32.06
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $178.19 million
  • Price / Sales: 10.70
  • Book Value: $2.04 per share
  • Price / Book: 13.36
  • EBIDTA: ($52,180,000.00)
  • Net Margins: -45.93%
  • Return on Equity: -40.38%
  • Return on Assets: -16.66%
  • Debt-to-Equity Ratio: 0.49%
  • Current Ratio: 4.11%
  • Quick Ratio: 4.11%
  • Average Volume: 480,295 shs.
  • Beta: 1.75
  • Short Ratio: 6.49

Frequently Asked Questions for FibroGen (NASDAQ:FGEN)

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.11. The firm had revenue of $26.89 million for the quarter, compared to analyst estimates of $26.02 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. View FibroGen's Earnings History.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

4 brokers have issued 1-year price objectives for FibroGen's shares. Their predictions range from $33.00 to $52.00. On average, they expect FibroGen's stock price to reach $40.67 in the next year. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

When did FibroGen IPO?

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.90%), BlackRock Inc. (6.97%), FMR LLC (2.65%), State Street Corp (2.35%), Janus Capital Management LLC (2.12%) and ECOR1 CAPITAL, LLC Total Shares: 1,322,991 (1.90%). Company insiders that own FibroGen stock include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Thomas F Kearns, Jr. View Institutional Ownership Trends for FibroGen.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Morgan Stanley, Candriam Luxembourg S.C.A., Oxford Asset Management, TFS Capital LLC, Pinnacle Associates Ltd., Trexquant Investment LP and Franklin Street Advisors Inc. NC. Company insiders that have sold FibroGen stock in the last year include K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff and Thomas F Kearns Jr. View Insider Buying and Selling for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bogle Investment Management L P DE, Prudential Financial Inc., FMR LLC, State Street Corp, Acadian Asset Management LLC and Strs Ohio. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of FibroGen stock cost?

One share of FibroGen stock can currently be purchased for approximately $27.25.

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.67 (49.24% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/18/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
1/18/2017Stifel NicolausReiterated RatingPositive$33.00N/AView Rating Details
11/9/2016Leerink SwannReiterated RatingBuy$52.00N/AView Rating Details
8/9/2016Credit Suisse Group AGReiterated RatingBuy$37.00N/AView Rating Details
2/22/2016Goldman Sachs Group IncLower Price Target$34.00 -> $31.00N/AView Rating Details
12/4/2015Citigroup IncInitiated CoverageBuy$40.00N/AView Rating Details
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00N/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for FibroGen (NASDAQ:FGEN)
Earnings by Quarter for FibroGen (NASDAQ:FGEN)
Earnings History by Quarter for FibroGen (NASDAQ:FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for FibroGen (NASDAQ:FGEN)
2017 EPS Consensus Estimate: ($1.98)
2018 EPS Consensus Estimate: ($1.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.77)($0.48)($0.63)
Q2 20172($0.47)($0.45)($0.46)
Q3 20172($0.46)($0.22)($0.34)
Q4 20172($0.58)($0.53)($0.56)
Q1 20181($0.87)($0.87)($0.87)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181$0.77$0.77$0.77
Q4 20181($0.76)($0.76)($0.76)
(Data provided by Zacks Investment Research)


Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for FibroGen (NASDAQ:FGEN)
Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 47.74%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.00View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.20View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.00View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.12View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.00View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.00View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.44View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.12View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.24View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.00View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.52View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.00View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.84View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.00View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.08View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.42View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.00View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.30View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.52View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.52View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.52View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.40View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.26View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.42View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.48View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for FibroGen (NASDAQ:FGEN)
Latest Headlines for FibroGen (NASDAQ:FGEN)
DateHeadline logo$34.74 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter - May 27 at 7:33 AM logoZacks: Brokerages Anticipate FibroGen Inc (FGEN) Will Announce Earnings of -$0.48 Per Share - May 26 at 12:30 AM logoETFs with exposure to FibroGen, Inc. : May 22, 2017 - May 22 at 4:50 PM logoFibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 4:56 PM logoFibroGen Inc (FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares - May 17 at 11:15 PM logoInsider Selling: FibroGen Inc (FGEN) CEO Sells 18,900 Shares of Stock - May 17 at 10:51 PM logoFibroGen Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares - May 17 at 10:28 PM logoAkebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact - May 15 at 4:50 PM logoInsider Selling: FibroGen Inc (FGEN) Insider Sells 5,000 Shares of Stock - May 12 at 8:01 PM logoEquities Analysts Offer Predictions for FibroGen Inc's FY2017 Earnings (FGEN) - May 12 at 12:54 PM logoFibroGen Inc (FGEN) to Post Q2 2017 Earnings of ($0.47) Per Share, Leerink Swann Forecasts - May 12 at 10:21 AM logoFibroGen Inc (FGEN) Announces Quarterly Earnings Results - May 11 at 2:20 PM logoEdited Transcript of FGEN earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 5:19 PM logoFibroGen Inc Expected to Post Q2 2017 Earnings of ($0.29) Per Share (FGEN) - May 10 at 8:28 AM logoInvestor Network: FibroGen, Inc. to Host Earnings Call - May 9 at 5:03 PM logoFibroGen Reports First Quarter 2017 Financial Results - May 9 at 5:03 PM logoLeerink Swann Analysts Reduce Earnings Estimates for FibroGen Inc (FGEN) - May 9 at 12:20 PM logoFibroGen Inc (FGEN) Downgraded by Zacks Investment Research to "Sell" - May 9 at 12:04 AM logoFibroGen Inc (FGEN) Stock Rating Lowered by Zacks Investment Research - May 8 at 11:58 PM logoShould You Sell FibroGen, Inc (FGEN) Before Earnings? - May 5 at 5:23 PM logoWhat's in the Cards for Repros (RPRX) this Earnings Season? - May 5 at 5:23 PM logoArena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store? - May 4 at 12:27 PM logoWhat's in the Cards for Allergan (AGN) this Earnings Season? - May 4 at 12:27 PM logo$26.02 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter - May 4 at 12:02 PM logoWhat's in the Cards for Inovio (INO) This Earnings Season? - May 3 at 10:01 PM logoJazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint? - May 3 at 5:00 PM logoPuma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? - May 3 at 5:00 PM logoKite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards? - May 3 at 5:00 PM logoFibroGen to Report First Quarter Financial Results on May 9, 2017 - May 3 at 8:42 AM logoFibroGen (FGEN) Earning Somewhat Critical Press Coverage, Report Shows - May 2 at 9:38 PM logoFibroGen Inc (FGEN) Expected to Announce Earnings of -$0.63 Per Share - May 2 at 8:02 PM logoGW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect? - May 2 at 7:35 PM logoWhat's in Store for Catalyst (CPRX) Stock in Q1 Earnings? - May 2 at 7:35 PM logoWhat's in Store for Zoetis (ZTS) Stock This Earnings Season? - May 1 at 4:59 PM logoRadius Health (RDUS) Q1 Earnings: What's in Store? - May 1 at 4:59 PM logoFibroGen (FGEN) Receives News Sentiment Score of 0.10 - April 29 at 2:51 PM logoIs Intercept (ICPT) Poised for a Beat This Earnings Season? - April 28 at 11:17 PM logoInsider Selling: FibroGen Inc (FGEN) VP Sells 6,500 Shares of Stock - April 28 at 12:00 AM logoFibroGen Inc (FGEN) Insider Sells $140,000.00 in Stock - April 28 at 12:00 AM logoWhat's in the Cards for Merrimack (MACK) in Q1 Earnings? - April 27 at 5:47 PM logoFibroGen Inc (FGEN) CEO Sells $1,040,081.12 in Stock - April 26 at 10:54 PM logoFibroGen (FGEN) Receiving Somewhat Negative Press Coverage, Report Shows - April 26 at 1:24 PM logoCommit To Buy FibroGen At $20, Earn 12.8% Annualized Using Options - April 25 at 4:51 PM logoAkebia Expands Anemia Pill Partnership to Include Europe, China Rights - April 25 at 4:51 PM logoFibroGen Inc to Post Q1 2017 Earnings of ($0.48) Per Share, William Blair Forecasts (FGEN) - April 24 at 7:25 AM logoFibroGen (FGEN) Receiving Somewhat Favorable News Coverage, Report Finds - April 23 at 6:34 PM logoFibroGen Inc (FGEN) Forecasted to Earn FY2019 Earnings of $5.30 Per Share - April 21 at 5:37 PM logoFibroGen (FGEN) Earning Somewhat Positive Media Coverage, Report Shows - April 20 at 5:09 PM logoInsider Selling: FibroGen Inc (FGEN) Director Sells 2,000 Shares of Stock - April 19 at 8:23 PM logoFibroGen (FGEN) Given Daily News Sentiment Rating of 0.00 - April 17 at 3:16 PM



FibroGen (FGEN) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff